-
1.发明公开公开(公告)号：US20230192870A1
公开(公告)日：2023-06-22
申请号：US17812592
申请日：2022-07-14
发明人： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC分类号： C07K16/28 , A61K47/69 , A61K47/64 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/395 , C12Q1/6886
CPC分类号： C07K16/2866 , A61K47/6929 , A61K47/643 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/3955 , C07K16/2818 , C12Q1/6886 , A61K2039/507
摘要： The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
公开(公告)号：US11421034B2
公开(公告)日：2022-08-23
申请号：US16646690
申请日：2018-09-12
发明人： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC分类号： C07K16/28 , A61K47/69 , A61K47/64 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/395 , C12Q1/6886 , A61K39/00
摘要： The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
公开(公告)号：US20210009697A1
公开(公告)日：2021-01-14
申请号：US16646690
申请日：2018-09-12
发明人： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC分类号： C07K16/28 , A61K31/7068 , A61K31/513 , A61K39/395 , A61K31/337 , A61K47/69 , A61K47/64 , C12Q1/6886 , A61P35/00
摘要： The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
公开(公告)号：US20190125833A1
公开(公告)日：2019-05-02
申请号：US16095974
申请日：2017-04-24
CPC分类号： A61K38/1774 , A61P7/06 , A61P21/00 , A61P25/28 , C07K14/70503 , C07K2319/30
摘要： Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
-
5.发明申请公开(公告)号：US20170145102A1
公开(公告)日：2017-05-25
申请号：US15358756
申请日：2016-11-22
发明人： Kristen Pierce , Janine Powers , Servando Palencia , Robert Sikorski , Majid Ghoddusi , Kartik Krishnan
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/507 , A61K2039/55 , C07K16/2818 , C07K16/2896 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K16/3084 , C07K2317/34 , C07K2317/41 , G01N33/5091 , G01N33/57407 , G01N33/57446 , G01N33/57492 , G01N2333/71 , G01N2800/52
摘要： Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
-
公开(公告)号：US10799559B2
公开(公告)日：2020-10-13
申请号：US16095974
申请日：2017-04-24
IPC分类号： A61K38/17 , C07K14/705 , A61P7/06 , A61P21/00 , A61P25/28
摘要： Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
-
公开(公告)号：US20170145103A1
公开(公告)日：2017-05-25
申请号：US15358941
申请日：2016-11-22
发明人： Kristen Pierce , Janine Powers , Servando Palencia , Robert Sikorski , Majid Ghoddusi , Kartik Krishnan
IPC分类号： C07K16/28 , G01N33/574 , G01N33/50 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/507 , A61K2039/55 , C07K16/2818 , C07K16/2896 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K16/3084 , C07K2317/34 , C07K2317/41 , G01N33/5091 , G01N33/57407 , G01N33/57446 , G01N33/57492 , G01N2333/71 , G01N2800/52
摘要： Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.
-
公开(公告)号：US11975046B2
公开(公告)日：2024-05-07
申请号：US18343944
申请日：2023-06-29
摘要： The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
-
9.发明授权公开(公告)号：US11447553B2
公开(公告)日：2022-09-20
申请号：US15358756
申请日：2016-11-22
发明人： Kristen Pierce , Janine Powers , Servando Palencia , Robert Sikorski , Majid Ghoddusi , Kartik Krishnan
IPC分类号： C07K16/28 , C07K16/30 , A61K39/00 , G01N33/50 , G01N33/574
摘要： Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
-
公开(公告)号：US20140274898A1
公开(公告)日：2014-09-18
申请号：US14185086
申请日：2014-02-20
IPC分类号： C07K14/71 , A61K31/506 , A61K31/473 , A61K38/17
CPC分类号： C07K14/71 , A61K8/64 , A61K31/473 , A61K31/506 , A61K38/179 , A61Q7/00
摘要： The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
摘要翻译： 促进毛发生长的方法本发明涉及一种促进毛发生长的方法，包括以足以促进毛发生长的量施用包含天然FGFR3 ECDs，变体，片段和融合分子的成纤维细胞生长因子受体3（FGFR3）细胞外结构域（ECD） 头发生长。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
